The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Hepatocellular carcinoma in Central Europe: prognostic features and survival
Open accessAbstract
BACKGROUND AND AIMS: We investigated the influence of baseline characteristics of patients with hepatocellular carcinoma (HCC) on prognosis and developed a multivariate Cox model predicting survival. All patients were from Central Europe. METHODS: All 245 patients seen at the Department of Gastroenterology and Hepatology at the University of Vienna, Austria, from July 1991 to March 1998 were included in this retrospective study. Nineteen different clinical characteristics and survival time from date of diagnosis were noted. Factors determining survival time were analysed by univariate and multivariate analysis using Cox proportional hazard regression models and a new classification model was constructed. The validity of this model was tested on an independent group of 89 patients, seen from April 1998 to September 1999. RESULTS: Median survival in patients with HCC was 8.0 months. In a multivariate analysis bilirubin (>2 mg/dl), portal vein thrombosis, prothrombin time (<70%), alpha fetoprotein (>180 μg/l), tumour mass >50%, and enlarged lymph nodes were independent predictors of survival. A newly constructed Cox proportional hazard model (Vienna survival model for HCC=VISUM-HCC) identified three disease stages with different durations of survival (median survival stage 1, 15.2 months; stage 2, 7.2 months; and stage 3, 2.6 months; p=0.00001). Applying the VISUM-HCC survival model to patients in Okuda stage 2 identified subgroups with an excellent and very poor prognosis for which different treatment modalities should be offered. CONCLUSIONS: Our patients with HCC had a poor median survival of eight months. Six easily measurable clinical variables were significant predictors of survival in patients with HCC. The new VISUM-HCC survival model may be useful for stratifying patients with HCC for various clinical treatment modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Cited by
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort†
Marrero, J. A., Fontana, R. J., Barrat, A., Askari, F., Conjeevaram, H. S., Su, G. L., & Lok, A. S. (2005) · Hepatology · doi:10.1002/hep.20636 · Cited by 637
Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burden
Nguyen, V. T. T., Law, M. G., & Dore, G. J. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01117.x · Cited by 302
Cancer and liver cirrhosis: implications on prognosis and management
Pinter, M., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000042 · Cited by 295
Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients
Tateishi, R., Yoshida, H., Shiina, S., Imamura, H., Hasegawa, K., Teratani, T., Obi, S., Sato, S., Koike, Y., Fujishima, T., et al. (2005) · Gut · doi:10.1136/gut.2003.035055 · Cited by 273
Metadata
- Authors
- Schöniger-Hekele, M., Müller, C., Kutilek, M., Oesterreicher, C., Ferenci, P., & Gangl, A.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2001-01-01
- Volume
- 48
- Issue
- 1
- Pages
- 103-109
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W1979809642
- Cited by
- 228
- References
- 1
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatocellular carcinoma in Central Europe: prognostic features and survival. https://app.cochat.ai/papers/10.1136/gut.48.1.103
- The paper
- Schöniger-Hekele, M., Müller, C., Kutilek, M., Oesterreicher, C., Ferenci, P., & Gangl, A. (2001). Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. https://doi.org/10.1136/gut.48.1.103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.